NEW YORK, June 16 - Diversa will receive $1.38 million from the Department of Defense's chemical and biological defense initiatives fund for proteomics-related biodefense research, the San Diego-based microbial genomics firm said today.
The award will support the development of diagnostic and therapeutic antibodies against anthrax as well as the identification of new targets associated with anthrax and plague pathology, the company said.
The DOD funds will be applied to three projects at Diversa: the identification of an optimized antibody against anthrax; proteomics analysis of blood serum from the survivors of the fall 2001 anthrax attacks to identify novel targets for therapeutics; and the proteomics-based Identification of novel protein targets associated with plague.
The company said its proteomics analysis method relies on 3D liquid chromatography directly coupled with tandem mass spectroscopy.
The research is part of Diversa's "Rapid, Antibody-Based Biological Countermeasures" (RABBC) biodefense program, which aims to develop a collection of novel human antibodies for diagnostic detection and immunity protection against pathogens and toxins.